UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 14, 2024

 

VolitionRx Limited

(Exact name of registrant as specified in its charter)

 

Delaware

001-36833

91-1949078

(State or other jurisdiction

(Commission

(IRS Employer

of Incorporation)

File Number)

Identification Number)

 

1489 West Warm Springs Road, Suite 110

Henderson, Nevada

89014

(Address of Principal Executive Offices)

(Zip Code)

 

+1 (646) 650-1351

(Registrant’s telephone number, including area code)

 

Not applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Trading Symbol(s)

 

Name of Each Exchange on which Registered

Common Stock,par value $0.001 per share

 

VNRX

 

NYSE American, LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

VOLITIONRX LIMITED

Form 8-K

Current Report

 

Item 2.02. Results of Operations and Financial Condition.

 

The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

On November 14, 2024, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for the quarter ended September 30, 2024. The Company also confirmed its conference call to be held on November 15, 2024 at 8:30 a.m. U.S. Eastern Time. Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.

 

Item 9.01. Financial Statements and Exhibits.

 

 

(d)

Exhibits.

 

Exhibit

Number

 

 

Description

99.1

 

Press Release of VolitionRx Limited, dated November 14, 2024.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)

 

 
2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

VOLITIONRX LIMITED

 

 

Date: November 14, 2024

By:

/s/ Cameron Reynolds

 

 

Cameron Reynolds

 

 

 

Chief Executive Officer & President

 

 

 
3

 

 

EXHIBIT INDEX

 

Exhibit

Number

 

 

Description

99.1

 

Press Release of VolitionRx Limited, dated November 14, 2024.

 

 
4

 

nullv3.24.3
Cover
Nov. 14, 2024
Cover [Abstract]  
Entity Registrant Name VolitionRx Limited
Entity Central Index Key 0000093314
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date Nov. 14, 2024
Entity File Number 001-36833
Entity Incorporation State Country Code DE
Entity Tax Identification Number 91-1949078
Entity Address Address Line 1 1489 West Warm Springs Road
Entity Address Address Line 2 Suite 110
Entity Address City Or Town Henderson
Entity Address State Or Province NV
Entity Address Postal Zip Code 89014
City Area Code 646
Local Phone Number 650-1351
Security 12b Title Common Stock,par value $0.001 per share
Trading Symbol VNRX
Security Exchange Name NYSE
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
VolitionRX (AMEX:VNRX)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more VolitionRX Charts.
VolitionRX (AMEX:VNRX)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more VolitionRX Charts.